Matching articles for "April 7"

In Brief: Meningococcal Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • April 7, 2008;  (Issue 1283)
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR,...
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines (Med Lett Drugs Ther 2005; 47:29) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread.

A single oral dose of ciprofloxacin (Cipro, and others) 500 mg has been used for prophylaxis after close contact with infected patients. Oral rifampin (Rifadin, and others) 600 mg (10 mg/kg for children) q12h for 2 days, a single IM injection of ceftriaxone (Rocephin, and others) 250 mg (125 mg for children), or a single oral dose of azithromycin (Zithromax, and others) 500 mg (10 mg/kg for children) are reasonable alternatives.

Download U.S. English
Med Lett Drugs Ther. 2008 Apr 7;50(1283):25 | Show Full IntroductionHide Full Introduction

Simcor: A Niacin/Simvastatin Combination

   
The Medical Letter on Drugs and Therapeutics • April 7, 2008;  (Issue 1283)
The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin (Niaspan) with a generic statin. Niaspan/simvastatin (Simcor - Abbott) is approved for use in patients with...
The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin (Niaspan) with a generic statin. Niaspan/simvastatin (Simcor - Abbott) is approved for use in patients with hypercholesterolemia or mixed dyslipidemia (high LDL-cholesterol, low HDL-cholesterol and high serum triglycerides). Niaspan/lovastatin (Advicor) was marketed previously for the same indications.
Med Lett Drugs Ther. 2008 Apr 7;50(1283):25-6 | Show Full IntroductionHide Full Introduction

Nilotinib (Tasigna) for CML

   
The Medical Letter on Drugs and Therapeutics • April 7, 2008;  (Issue 1283)
Nilotinib (Tasigna - Novartis), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of Philadelphia chromosome-positive (Ph+) chronic or accelerated phase chronic myelogenous leukemia (CML)...
Nilotinib (Tasigna - Novartis), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of Philadelphia chromosome-positive (Ph+) chronic or accelerated phase chronic myelogenous leukemia (CML) in patients resistant to or intolerant of imatinib (Gleevec).
Med Lett Drugs Ther. 2008 Apr 7;50(1283):26-7 | Show Full IntroductionHide Full Introduction

Tadalafil (Cialis) Once a Day for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • April 7, 2008;  (Issue 1283)
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil (Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil (Viagra) and vardenafil...
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil (Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil (Viagra) and vardenafil (Levitra), the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.
Med Lett Drugs Ther. 2008 Apr 7;50(1283):27-8 | Show Full IntroductionHide Full Introduction